ICCC Form 3 details CEO’s three option tranches at $5.90
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ImmuCell (ICCC) filed a Form 3 reporting initial beneficial ownership for its President and CEO. The filing lists three nonqualified stock options to purchase Common Stock at an exercise price of $5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
te Boekhorst Paul Francis Olivier
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Non Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non Qualified Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Non Qualified Stock Option (right to buy) — 25,327 shares (Direct)
Footnotes (1)
FAQ
What did ICCC disclose in this Form 3 filing?
It reported initial beneficial ownership for the President and CEO via three nonqualified stock options with a $5.90 exercise price.
What are the option amounts and exercise price for ICCC's CEO?
Three options for 25,327, 25,327, and 25,329 shares at an exercise price of $5.90 per share.
When do the CEO’s options become exercisable at ICCC?
They become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028.
When do the reported options expire?
Each option expires on 09/16/2035.
How do the options vest?
They vest in three increments as shown in the filing’s table.
What is the relationship of the reporting person to ICCC?
The reporting person is a Director and an Officer serving as President and CEO.
What is the ownership form for the options?
The filing lists the options as Direct (D) ownership.